COVID-19パンデミックは、パンデミックの初期段階で世界中の患者の神経医療サービスの進展を妨げました。しかし、政府の取り組みにより治療が再開されました。コロナ後、メンタルヘルス、うつ病、不安に対する注目が増加しました。これは、より多くの神経ケアを必要としたためです。例えば、2022年8月にFrontiers in Psychiatryに掲載された記事によると、米国ではCOVID-19にかかった後、約18.4%の人々が中等度から重度のうつ病を経験したと報告されています。同様に、2023年3月のKFF/CNNの調査によれば、女性の不安と抑うつ症状は36%に上昇し、男性の28%に対して高いことが示されています。同じ情報源はまた、2021年の全精神保健と物質使用障害の外来訪問のほぼ40%が遠隔医療を通じて行われたと述べています。したがって、パンデミックは人々の神経障害の増加を引き起こし、市場成長に大きな影響を与えました。

• 1 イントロダクション

  • 1.1 調査の前提条件と市場の定義

  • 1.2 本調査の範囲

• 2 調査手法

• 3 エグゼクティブサマリー

• 4 市場ダイナミクス

  • 4.1 市場概要

  • 4.2 市場の促進要因

    • 4.2.1 神経疾患の高い有病率

    • 4.2.2 病気の早期診断に対する意識の高まり

    • 4.2.3 増加する神経疾患の研究開発

  • 4.3 市場の抑制要因

    • 4.3.1 高額な診断と治療費

    • 4.3.2 神経用医薬品に関する厳しい規制

  • 4.4 ポーターのファイブフォース分析

    • 4.4.1 新規参入の脅威

    • 4.4.2 買い手・消費者の交渉力

    • 4.4.3 サプライヤーの交渉力

    • 4.4.4 代替品の脅威

    • 4.4.5 競合・競争状況の激しさ

• 5 市場セグメンテーション（市場規模別、金額、百万米ドル）

  • 5.1 国境を越えて

    • 5.1.1 てんかん

    • 5.1.2 アルツハイマー型認知症

    • 5.1.3 パーキンソン病

    • 5.1.4 多発性硬化症

    • 5.1.5 脳血管疾患

    • 5.1.6 その他の疾患

  • 5.2 薬品タイプ別

    • 5.2.1 コリンエステラーゼ阻害剤

    • 5.2.2 NMDA受容体拮抗薬

    • 5.2.3 抗てんかん薬

    • 5.2.4 抗精神病薬と抗うつ薬

    • 5.2.5 その他の医薬品

  • 5.3 流通チャネル別

    • 5.3.1 病院内薬局

    • 5.3.2 オンライン薬局

    • 5.3.3 小売薬局

  • 5.4 地域別

    • 5.4.1 北米

      • 5.4.1.1 米国
      • 5.4.1.2 カナダ
      • 5.4.1.3 メキシコ

    • 5.4.2 ヨーロッパ

      • 5.4.2.1 ドイツ
      • 5.4.2.2 英国
      • 5.4.2.3 フランス
      • 5.4.2.4 イタリア
      • 5.4.2.5 スペイン
      • 5.4.2.6 その他のヨーロッパ

    • 5.4.3 アジア太平洋

      • 5.4.3.1 中国
      • 5.4.3.2 日本
      • 5.4.3.3 インド
      • 5.4.3.4 オーストラリア
      • 5.4.3.5 韓国
      • 5.4.3.6 その他のアジア太平洋

    • 5.4.4 中東・アフリカ

      • 5.4.4.1 GCC地域
      • 5.4.4.2 南アフリカ
      • 5.4.4.3 その他の中東・アフリカ

    • 5.4.5 南米

      • 5.4.5.1 ブラジル
      • 5.4.5.2 アルゼンチン
      • 5.4.5.3 その他の南米

• 6 競合情勢

  • 6.1 企業プロファイル

    • 6.1.1 Merck & Co.,Inc

    • 6.1.2 AstraZeneca

    • 6.1.3 Abbott

    • 6.1.4 F. Hoffmann-La Roche Ltd

    • 6.1.5 Novartis AG

    • 6.1.6 Pfizer Inc

    • 6.1.7 Sanofi

    • 6.1.8 Bayer AG

    • 6.1.9 Johnson & Johnson Private Limited

    • 6.1.10 Teva Pharmaceutical Industries Ltd

• 7 市場機会と今後の動向

The Neurological Disorder Drugs Market is expected to register a CAGR of 5.6% during the forecast period.

The COVID-19 pandemic hampered the progress of neurological healthcare services for patients worldwide in the initial phases of the pandemic. However, treatment resumed following government initiatives. The focus on mental health, depression, and anxiety increased post-COVID as it demanded more neurological care. For instance, an article published by Frontiers in Psychiatry in August 2022 stated that around 18.4% of people in the United States experienced moderate to severe depression after suffering from COVID-19 disease. Similarly, according to a KFF/CNN survey of March 2023, symptoms of anxiety and depression elevated among women, which is 36% compared to men's at 28% in February 2023. The same source also stated that nearly 40% of all mental health and substance use disorder outpatient visits were delivered through telehealth in 2021. Hence, the pandemic led to an increase in neurological disorders among people, which significantly had a significant impact on market growth.

The factors expected to drive the market growth include the increasing prevalence of neurological diseases, rising awareness for early disease diagnosis, and increasing R&D for neurological disorders. Worldwide, neurological illnesses are a leading cause of disability and mortality. Neurodegenerative disorders such as Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS) cause significant morbidity and mortality in the aged population worldwide. Many organizations across the globe are taking substantial steps to reduce the incidence of neurological diseases. For instance, according to the WHO report published in April 2022, the intersectoral global action plan on epilepsy and other neurological disorders 2022-2031 represents an unprecedented opportunity to address the burden of neurological illnesses throughout and after the pandemic. This is expected to create a high demand for neurological drugs. Such initiatives to reduce neurological disorders are expected to drive the market during the forecast period.

The market for neurological drugs is predicted to rise due to the high prevalence of neurological illnesses such as dementia, autism, Alzheimer's disease, and other rare diseases. For instance, according to the WHO's data published in April 2023, about 55 million people worldwide have dementia, and this is likely to rise to 78 million by 2030 and 139 million by 2050. The WHO also stated that the global financial burden of dementia was estimated to be USD 1.3 trillion in 2019 and is expected to climb to USD 2.8 trillion by 2030. Thus, this is projected to contribute to the market growth over the forecast period.

Furthermore, extensive research and developments for Alzheimer's are also projected to contribute to the market growth. For instance, an article published by Alzheimer's Association in May 2022 stated that as of January 25, 2022, there were 143 agents in 172 clinical trials for AD. The pipeline included 31 agents in 47 trials in Phase 3, 82 agents in 94 trials in Phase 2, and 30 agents in 31 trials in Phase 1. Advances in drug design, outcome measures, use of biomarkers, and trial conduct promise to accelerate the delivery of new and better treatments for patients with Alzheimer's. Such R&D initiatives are expected to boost the market for neurological drugs. Drug approvals for neurological disorders are also likely to drive market growth. For instance, in May 2023, Biophore India Pharmaceuticals announced that it had received approval from the Central Drugs Standard Control Organisation (CDSCO) to manufacture and market Cannabidiol Solution 100mg/ml for neuro disorders in India.

However, the high cost of diagnosis and treatment as well as stringent regulations associated with the neurological drugs is expected to restrain the market's growth over the forecast period.

Neurological Disorder Drugs Market Trends

The Alzheimer's Disease Segment is Expected to Hold a Significant Share in the Neurological Disorders Drugs Market Over the Forecast Period

Alzheimer's disease is becoming more common as the global population ages, which increases the disease's incidence and provides opportunities for growth in the market for Alzheimer's treatment. For instance, as per the Alzheimer's Disease Facts And Figures 2023 report, Americans aged 65 years and older are projected to grow from 58 million in 2021 to 88 million by 2050. The above source also stated that in 2023 about 2.4 million people with Alzheimer's dementia are likely to be 85 years of age or older and are projected to account for 33% of all people with Alzheimer's dementia. This number is projected to reach 6.7 million people by 2060, accounting for about 48% of all people 65 years and older with Alzheimer's dementia. As the risk of dementia rises with age, it is anticipated that the number and percentage of people with Alzheimer's or other dementias will likely increase in the coming years, which is projected to create demand for advanced treatment, thereby boosting the market growth.

Besides, various medications for Alzheimer's therapy are in development and are projected to launch shortly, which is likely to contribute to the market growth over the forecast period. For instance, in January 2023, through the Accelerated Approval process, Leqembi (lecanemab-irmb) received United States Food and Drug Administration (FDA) approval to treat Alzheimer's disease. eqembi is the second drug in a newly approved class of Alzheimer's disease that addresses the illness's basic pathogenesis. Similarly, in May 2023, the United States FDA granted the supplemental approval of Rexulti (brexpiprazole) oral tablets for treating agitation associated with dementia due to Alzheimer's disease. Such approvals for neurological drugs are expected to accelerate market growth.

North America is Expected to Hold a Significant Share Over the Forecast Period

North America is projected to account for the largest share of the global neurological disorder drugs market due to various approvals, collaborations, acquisitions, and increasing neurological disorders in the region.

Increasing incidences of various neurological disorders are the prominent reason expected to drive market growth. For instance, according to the Parkinson's Disease Foundation's data from 2023, in the United States, almost a million people have Parkinson's disease (PD), and by 2030, the number is expected to reach 1.2 million. Also, Parkinson's disease is the most common neurodegenerative condition after Alzheimer's disease. Hence, the huge burden of PD is likely to contribute to the market growth over the forecast Period.

Strategic activities such as new product development, approvals, collaborations, and acquisitions in the United States are driving the growth of the neurological disorder drugs market. For instance, in March 2023, Pfizer Inc. announced that ZAVZPRETTM (zavegepant), the calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray for the immediate treatment of migraine with or without aura in adults, has received approval from the United States FDA. Thus, product approvals in the country are anticipated to drive the market's growth.

Neurological Disorder Drugs Industry Overview

The neurological disorder drugs market is fragmented, competitive and consists of several major players. The competitive landscape includes an analysis of a few international and local companies that hold market shares and are well-known including Merck & Co., Inc, AstraZeneca, Abbott, F. Hoffmann-La Roche Ltd., and Novartis AG.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

• 1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition

  • 1.2 Scope of the Study

• 2 RESEARCH METHODOLOGY

• 3 EXECUTIVE SUMMARY

• 4 MARKET DYNAMICS

  • 4.1 Market Overview

  • 4.2 Market Drivers

    • 4.2.1 High Prevalence of Neurological Diseases

    • 4.2.2 Rising Awareness for Early Disease Diagnosis

    • 4.2.3 Increasing Number of Research and Development for Neurological Diseases

  • 4.3 Market Restraints

    • 4.3.1 High Cost for Diagnosis and Treatment

    • 4.3.2 Stringent Regulations Associated with the Neurological Drugs

  • 4.4 Porter's Five Force Analysis

    • 4.4.1 Threat of New Entrants

    • 4.4.2 Bargaining Power of Buyers/Consumers

    • 4.4.3 Bargaining Power of Suppliers

    • 4.4.4 Threat of Substitute Products

    • 4.4.5 Intensity of Competitive Rivalry

• 5 MARKET SEGMENTATION (Market Size by Value - USD Million)

  • 5.1 By Disorders

    • 5.1.1 Epilepsy

    • 5.1.2 Alzheimer's Disease

    • 5.1.3 Parkinson's Disease

    • 5.1.4 Multiple Sclerosis

    • 5.1.5 Cerebrovascular Disease

    • 5.1.6 Other Disorders

  • 5.2 By Drug Type

    • 5.2.1 Cholinesterase Inhibitors

    • 5.2.2 NMDA Receptor Antagonists

    • 5.2.3 Antiepileptic

    • 5.2.4 Antipsychotic and Antidepressant

    • 5.2.5 Other Drugs Type

  • 5.3 By Distribution Channels

    • 5.3.1 Hospital Pharmacies

    • 5.3.2 Online Pharmacies

    • 5.3.3 Retail Pharmacies

  • 5.4 Geography

    • 5.4.1 North America

      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico

    • 5.4.2 Europe

      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe

    • 5.4.3 Asia-Pacific

      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific

    • 5.4.4 Middle East and Africa

      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa

    • 5.4.5 South America

      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

• 6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles

    • 6.1.1 Merck & Co.,Inc

    • 6.1.2 AstraZeneca

    • 6.1.3 Abbott

    • 6.1.4 F. Hoffmann-La Roche Ltd

    • 6.1.5 Novartis AG

    • 6.1.6 Pfizer Inc

    • 6.1.7 Sanofi

    • 6.1.8 Bayer AG

    • 6.1.9 Johnson & Johnson Private Limited

    • 6.1.10 Teva Pharmaceutical Industries Ltd

• 7 MARKET OPPORTUNITIES AND FUTURE TRENDS